In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma

Keyphrases

• Malignant Mesothelioma 100%
• Mesothelioma Cells 100%
• IC50 100%
• Gemcitabine 100%
• Epigallocatechin-3-gallate 100%
• Drug Combination 100%
• In Vitro Screening 100%
• Synergistic Interaction 66%
• Dose-response Curve 66%
• Tumor 33%
• Cancer Treatment 33%
• Neutral Red Uptake 33%
• Clinical Treatment 33%
• Fixed Ratio 33%
• Combined Treatment 33%
• Cytotoxicity 33%
• Drug Use 33%
• Asbestos 33%
• Cisplatin 33%
• Etoposide 33%
• IC50 Value 33%
• Paclitaxel 33%
• Apoptosis Rate 33%
• Caspase-3 33%
• Effective Therapy 33%
• Mesothelium 33%
• Antitumor Compounds 33%
• Combination Index 33%
• Raltitrexed 33%
• Lactic Dehydrogenase 33%
• Taurolidine 33%
• Neutral Red Uptake Assay 33%
• Necrosis Rate 33%
• α-tocopheryl Succinate 33%
• Serous Cavities 33%
• Clinical Standards 33%
• Isobologram 33%
• Additivity 33%
• Imatinib 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Mesothelioma 100%
• Ascorbic Acid 100%
• Combination Drug 100%
• In Vitro Screening 100%
• IC50 50%
• Epigallocatechin Gallate 37%
• Gemcitabine 37%
• Malignant Neoplasm 25%
• Neutral Red 25%
• Synergism 25%
• Neoplasm 12%
• Lactate Dehydrogenase 12%
• Cytotoxicity 12%
• Tocopherol 12%
• Cisplatin 12%
• Necrosis 12%
• Caspase 3 12%
• Etoposide 12%
• Paclitaxel 12%
• Succinic Acid 12%
• Raltitrexed 12%
• Taurolidine 12%
• Imatinib 12%